Navigation Links
Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Date:3/18/2008

DEERFIELD, Ill., March 18 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that its Board of Directors has approved the repurchase of an additional $2 billion of the company's common stock to be executed upon completion of the company's existing share repurchase authorization.

Baxter has less than $700 million of remaining authorization under its previous $2 billion share repurchase program that was authorized in March 2007. Shares will be repurchased in the open market at times and amounts determined by management based on its evaluation of market conditions and other factors.

In 2007, Baxter returned more than $2.5 billion to shareholders through both share repurchases and dividends. The company repurchased 34 million shares of common stock, for approximately $1.9 billion, and paid dividends totaling $704 million.

"We remain confident in our ongoing ability to generate strong cash flows," said Robert M. Davis, chief financial officer. "We expect to return significant value to shareholders through a disciplined approach to capital allocation and financial management, while accelerating our investment in R&D and new business development opportunities that position us for future growth."

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning the company's expected cash flows, investments in R&D, accelerating business development activities and share repurchases and investments. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company's ability to identify and execute on business development and R&D opportunities; continued strength in the company's financial position, including cash flows; alternative uses of funds including, but not limited to dividends, business development transactions, and other investments in the company's businesses; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.


'/>"/>
SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. KGI Elects Three New Members to Board of Trustees
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
5. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
6. BioLife Solutions Expands Scientific Advisory Board
7. NeurogesX Appoints New Director to the Board
8. Genstar Names Michael Hurt to Its Strategic Advisory Board
9. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
10. Bruce Pasternack Elected to Codexis Board
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... the association for the California life ... st Century Cures legislation in Congress. The bill passed ... and in the Senate on December 7 by a 94-5 ... , president & CEO of Biocom: "Today, Congress ... patients around the world. The measure culminates three years of ...
(Date:12/7/2016)... AUSTIN, Texas , Dec. 7, 2016 /PRNewswire/ ... development of revolutionary immunogene therapy treatments, today announced ... healthcare practice within a leading strategic communications and ... strategic communications program. The program will combine investor ... the objective of raising the profile of Genprex ...
(Date:12/7/2016)... December 7, 2016 Regen BioPharma Inc. ... Journal of Molecular Sciences a team of scientists in ... have demonstrated that expression of NR2F6 in patients with ... for NR2F6 in patient,s cervical cancer tissue as well as ... "This is an interesting study and the first that ...
(Date:12/7/2016)... ... 07, 2016 , ... JULABO USA is inviting visitors to ... website has been designed to provide the best user-friendly experience coupled with intuitive ... product information, read educational industry content as well as share information across all ...
Breaking Biology Technology:
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):